1 Persistent immune abnormalities discriminate post-COVID syndrome from 2 convalescence

Julia Sbierski-Kind^{1,2*}, Stephan Schlickeiser^{3,4}, Svenja Feldmann⁵, Veronica Ober⁵,
Eva Grüner⁵, Claire Pleimelding⁵, Leonard Gilberg⁵, Isabel Brand⁶, Nikolas Weigl⁷,
Mohamed I. M. Ahmed^{6,8}, Gerardo Ibarra^{2,9}, Michael Ruzicka^{9,10}, Christopher
Benesch^{9,11}, Anna Pernpruner^{9,11}, Elisabeth Valdinoci^{9,11}, Michael Hoelscher^{6,8},
Kristina Adorjan^{9,12}, Hans Christian Stubbe^{6,9,11}, Michael Pritsch^{6,8}, Ulrich Seybold⁵,
Johannes Bogner^{5,6}, Julia Roider^{5,6*} on behalf of the Post Covid Care and KoCo19
study groups

- 10
- 11

12 Affiliations:

- 13 1. Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität 14 München, Munich, Germany.
- 15 2. Department of Internal Medicine IV, Division of Diabetology, Endocrinology and
- 16 Nephrology, University Hospital, Eberhard-Karls-Universität Tübingen, Tübingen,
- 17 Germany.
- 18 3. Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
- and Humboldt- Universität zu Berlin, Institute of Medical Immunology,
- 20 Augustenburger Platz 1, 13353 Berlin, Germany.
- 4. Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center
- for Regenerative Therapies (BCRT), Charitéplatz 1, 10117 Berlin, Germany.
- 5. Department of Infectious Diseases, Department of Medicine IV, University
- 24 Hospital, Ludwig-Maximilians-Universität München, Munich, Germany
- 6. German Center for Infection Research (DZIF), Partner Site Munich, Munich,
- 26 Germany.
- 27 7. Department of Medicine IV, Division of Clinical Pharmacology, University Hospital,
- 28 Ludwig-Maximilians-Universität München, Munich, Germany
- 8. Division of Infectious Diseases and Tropical Medicine, University Hospital,
- 30 Ludwig-Maximilians-Universität München, Munich, Germany
- 9. COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-
- 32 Maximilians-Universität München, Munich, Germany.
- 10. Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität
- 34 München, Munich, Germany.
- 11. Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität
- 36 München, Munich, Germany
- 12. Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-
- 38 Maximilians-Universität München, Munich, Germany.
- 39

40 **Corresponding authors. Email:**

- $41 \qquad Julia. Roider @med.uni-muenchen.de, Julia. Sbierski-Kind @med.uni-tuebingen.de \\$
- 42 Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität
- 43 Müteche prepMulaiche, nor de stade hy at has not been certified by peer review and should not be used to guide clinical practice.

44 Abstract

Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and 45 regulate tissue development, repair, and pathology. Persistent clinical seguelae 46 beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome 47 (PCS), are increasingly recognized in convalescent individuals. ILCs have been 48 associated with the severity of COVID-19 symptoms but their role in the 49 50 development of PCS remains poorly defined. Here we used multiparametric immune phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent 51 decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-52 matched convalescent control groups at > 3 months after infection. Patients with 53 PCS showed elevated expression of chemokines and cytokines associated with 54 trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation 55 and repair (CXCL1, EGF, RANTES, IL1RA, PDGF-AA). These results define 56 immunological parameters associated with PCS and might help find biomarkers and 57 disease-relevant therapeutic strategies. 58

59

60 Keywords

Innate lymphoid cells, COVID-19, Post-COVID-19-Syndrome, immune activation,
 tissue immunology

63

64 Abbreviations

- 65 EFG: epidermal growth factor
- 66 FLT-3 Ligand: Fms-related tyrosine kinase 3 ligand

67 IF- γ : interferon γ

- 68 ILC: Innate lymphoid cells
- 69 ILCP: Innate lymphoid cell precursors
- 70 ILC2s: Group 2 innate lymphoid cells
- 71 IL: interleukin

- 72 IL1RA: interleukin-1 receptor antagonist
- 73 PBMCs: Peripheral blood mononuclear cells
- 74 PAIS: Post-acute infection syndromes (PAIS)
- 75 PC: Post-Covid
- 76 PCS: Post-COVID-Syndrome
- 77 PDGF-AA: platelet-derived growth factor A
- 78 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- 79 TNF: tumor necrosis factor
- 80 t-SNE: t-distributed stochastic neighbor embedding
- 81 VEGF: vascular endothelial growth factor

82

- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 55
- 94

95 Introduction

Viral infections can result in chronic symptoms that persist in previously healthy 96 convalescent individuals across a wide range of viral families, including Ebola virus, 97 influenza, Epstein-Barr virus, and dengue fever^{1,2}. The main symptoms are exertion 98 intolerance, fatigue, neurocognitive and sensory impairment, sleep disturbances, flu-99 like symptoms, myalgia/arthralgia, and a plethora of nonspecific symptoms³. These 100 post-acute infection syndromes (PAIS) are associated with autoimmunity and 101 endothelial dysfunction, affecting both large and small vessels^{3,4}; however, risk 102 103 factors and the underlying pathophysiology remain largely unknown.

The COVID-19 pandemic, caused by infection with severe acute respiratory 104 syndrome coronavirus 2 (SARS-CoV-2), has led to an increasing prevalence of 105 106 convalescent patients with prolonged and persistent sequelae following acute SARS-CoV-2 infection- known as 'long COVID' or 'post-COVID syndrome'⁵. The estimated 107 108 prevalence of PCS ranges from 5-50%⁶, thus presenting an enormous global health burden, and can affect both patients with mild or severe forms of acute COVID-19 109 110 disease⁷. Clinical symptoms include fatigue, malaise, depression, cognitive impairment, persistent cough, dyspnoea, palpitations, and headaches⁸. While the 111 acute phase of COVID-19 has been extensively studied, providing health care 112 professionals with efficient treatment options, the pathogenesis of PCS remains 113 unclear, with current hypotheses including autoimmunity, latent virus reactivation, 114 tissue, and endothelial damage⁹. 115

The extreme respiratory distress in patients with acute COVID-19 is mediated 116 117 primarily by immunopathology and systemic inflammation. Pathological immune signatures suggestive of T cell exhaustion, delayed bystander CD8⁺ T cell activation, 118 and higher plasma GM-CSF and CXCL10 levels are associated with severity of the 119 disease^{10,11,12}. Survivors of severe COVID-19 show persistent 120 immune 121 abnormalities, including elevated levels of pro-inflammatory cytokines¹³. In addition to systemic inflammation, SARS-CoV-2 infects endothelial cells, causing virus-122 mediated apoptosis and consecutive endotheliitis and, thus, may promote 123 endothelial damage and increased recruitment of activated immune cells into the 124 endothelium and surrounding tissue¹⁴. 125

126

Dysregulated respiratory CD8⁺ T cell responses may contribute to impaired tissue 127 conditions and development of pulmonary sequelae¹⁵. Recent work identified 128 persistent immunological dysfunction in patients with post-acute seguelae of COVID-129 19, including highly activated innate immune cells and marked differences in specific 130 circulating myeloid and lymphocyte populations^{16,17}. 131

Innate lymphoid cells (ILCs) are tissue-resident effector immune cells with crucial 132 roles in normal tissue development and remodeling^{18,19}. These cells also participate 133 in both protective and pathologic immune responses during lung tissue 134 perturbation^{20,21}. Several studies detected a reduction in total circulating ILCs in 135 severe COVID-19 patients, while relative group 2 innate lymphoid cells (ILC2) levels, 136 particularly NKGD⁺ ILC2s, were increased^{22,23}. Although ILCs appear central to lung 137 infection and repair, their role in PCS remains critically unexplored. 138

Here we used multicolor flow cytometry and multiplex cytokine assays on plasma 139 from (1) healthy, uninfected controls (n=32, 'HC'); (2) previously SARS-CoV-2-140 infected individuals in the convalescent phase without persistent symptoms (n=32, 141 convalescent controls, 'CC'); and (3) individuals with persistent symptoms following 142 acute COVID-19 (n=27, post-COVID, 'PC') to identify specific immunological 143 alterations, including ILCs, in PCS. Among the CC and PC groups, most participants 144 were non-hospitalized during acute SARS-CoV-2 infection and CC and PC 145 individuals had persistent symptoms for more than 12 weeks from the initial infection. 146 We found expanded circulating ILC precursors (ILCPs) in PC individuals while ILC2s 147 were decreased. Patients with persistent symptoms also displayed elevated pro-148 inflammatory cytokines (IL-8, IL-6), chemokines associated with trafficking of 149 immune cells (CCL19/MIP-3b, FLT3-Ligand), and endothelial inflammation and 150 151 repair (CXCL1, EGF, RANTES, PDGF-AA).

152

Results and Discussion 153

154

Clinical characteristics of study participants 155

Patients, enrolled in the Post-COVID-Care study at the LMU University Hospital 156 Munich, presented with persistent symptoms for more than 12 weeks following acute 157 SARS-CoV-2 infection (PC group; n=27) and were compared to convalescent 158 patients without persistent symptoms (CC group; n=32) and healthy controls (HC 159

group; n=32), enrolled in the KoCo19-index study (Fig. 1A). Clinical demographics of 160 both study cohorts are reported in **Table 1**. The PCS, convalescent, and healthy 161 control groups were well-matched in sex (67% female PC; 56% female CC; 53% 162 female HC; Chi-square: 1.185, d.f. = 2), age (mean 37.15 years old PC; mean 36.09 163 years old CC; mean 35.91 years old HC; Kruskal-Wallis test p=0.9276), and BMI 164 (mean BMI PC group 24.0kg/m²; mean BMI CC group 23.4kg/m²; mean BMI HC 165 group 25.2kg/m²; Kruskal-Wallis test p=0.3315) (Fig. 1B and Table 1). Only 2 166 patients with COVID-19 sequelae were hospitalized during acute infection, whereas 167 168 none of the convalescent study participants were hospitalized (Fig. 1C), reflecting that some patients experience long-term health-consequences after acute COVID-169 19, regardless of disease severity. For PC and CC groups, elapsed days since initial 170 SARS-CoV-2 infection were different in median times from acute disease (113 days 171 for PC group vs. 273 days for CC group; Mann-Whitney p= <0.0001) (Fig. 1D); 172 however, initial enrolment and collection of blood for immunophenotyping took place 173 more than 3 months after onset of COVID-19 and none of the convalescent 174 participants reported persistent symptoms after acute disease. Acute SARS-CoV-2 175 infections within the PC group occurred in the period when the Omicron BA.2 176 177 variants were dominant (between January and March 2022), whereas participants of the convalescent group were confirmed to be infected with SARS-CoV-2 between 178 March and April 2020, when parental strains drove the majority of new cases. While 179 several risk factors, including comorbidities and virus variants, have been identified 180 for the development of PCS²⁴, clinical symptoms are similar for different SARS-CoV-181 2 strains, with the exception of musculoskeletal pain, where chronic burden may be 182 lower for Omicron compared to Delta variants²⁵. Consistent with numerous previous 183 reports of PCS, the most common reported symptoms included constitutional 184 symptoms, such as fatigue (93%) and insomnia (41%), and neurological symptoms, 185 such as impaired alertness (74%), memory impairment (59%), and impaired speech 186 (56%). Cardiac symptoms, including palpitations (59%), chest pain (52%), and 187 reduced muscular strength (26%) were also a common complaint (Fig. 1E). 188

189

190 **Pro-inflammatory cytokines and growth factors are elevated in PCS**

In COVID-19 patients with severe disease, cytokine storm and uncontrolled inflammatory responses, including endothelial inflammation and associated tissue damage, are recognized as one of the driving immunopathological features that can

lead to death¹⁰. To uncover the immunological dysregulation in PCS, we quantified 194 46 molecular analytes in the plasma of patients from the CC and PC groups >3 195 months after acute SARS-CoV-2 infection using a multiplex cytokine assay and 196 compared them to healthy controls. Four key pro-inflammatory cytokines (interleukin-197 8 (IL-8), IL-6, interleukin-1 receptor antagonist (IL-1Ra) and IL-1a) were elevated in 198 the PC group compared to the CC and HC groups (Fig. 2A, Suppl. Fig. 1), while no 199 difference was observed in transforming growth factor alpha (TGF-a), IL-7, IL-5, IL-4, 200 IL-13, IL-10, tumor necrosis factor (TNF α), interferon y (IFN-y) and IL-1 β (**Suppl.** 201 Fig.1). IL-8 has been previously associated with a prothrombotic neutrophil 202 phenotype in severe COVID-19 and blocking IL-8 signaling reduced SARS-CoV-2 203 spike protein-induced, human ACE2-dependent pulmonary microthrombosis in 204 mice²⁶. Surprisingly, levels of IL-8 and IL-6 were lower in CC compared to HCs, 205 whereas other pro-inflammatory cytokines were not different between these groups 206 (Fig. 2A, Suppl. Fig. 1). IL-1Ra was 2.16-fold higher in the PC group compared to 207 the HC group and 2.22-fold higher compared to the CC group; other pro-208 inflammatory cytokines were only slightly increased (Fig. 2A, Suppl. Fig.1). Several 209 chemokines (RANTES, MIP3b, CXCL1) and growth factors (Fms-related tyrosine 210 211 kinase 3 ligand (FLT-3 Ligand), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor A (PDGF-AA)), that could be 212 associated with trafficking of immune cells (MIP3b, FLT3-Ligand) and endothelial 213 inflammation (CXCL1, EGF, RANTES, PDGF-AA), CD40L and Granzyme B were 214 also elevated in PC participants compared to both CC and HC groups (Fig. 2A, 215 Suppl. Fig.1). Interestingly, Eotaxin (CCL11), monocyte chemoattractant protein 1 216 (MCP1), and IL-12p70 were decreased in PC patients compared to both 217 convalescent and healthy controls (Suppl. Fig. 1); some of these chemokines were 218 associated with severe cases of acute COVID-19²⁷. Importantly, programmed death-219 ligand 1 (PD-L1) was increased in the persistent symptom group compared to both 220 convalescent and healthy control groups, consistent with previous reports, 221 highlighting the prognostic role of sPD-L1 in COVID-19 patients²⁸ (Suppl. Fig.1). 222 Although most plasma samples from the CC group were taken at month 8 after acute 223 COVID-19 infection while samples from the PC group were taken at month 4, 224 challenging direct comparison of persistent symptom and convalescent groups, 225 several studies have shown that pro-inflammatory cytokines remained significantly 226 elevated in PC patients at month 8 after acute infection¹⁷. Together, these data 227

suggest persistent immune abnormalities in patients suffering from post-acutesequelae of COVID-19.

230

231 Circulating ILCPs are elevated in PC patients with concurrent decrease in 232 ILC2s

To investigate circulating ILC levels via flow cytometry in PCS, convalescent and 233 healthy controls, we used a well-established gating strategy²⁹ (Suppl. Fig.2). Lin⁻ 234 CD127⁺ ILC subsets were defined as CD117⁻CRTH2⁻ ILC1s, CD117⁺ ILC 235 236 progenitors (ILCP)³⁰, and CRTH2⁺ ILC2s. We used CD56 as a marker of activated or ILC3/NK cell-committed ILCP and CD45RA for naïve ILCP²⁹. Recent work 237 discovered CD45RA⁺ naïve-like ILCs, lacking proliferative activity, indicative of 238 cellular quiescence³¹. To visualize multiple dimensions in simple two dimensional 239 plots and compare flow cytometry data between groups, we used stochastic 240 neighbor embedding analysis (Fig. 2 B, C). We found increased expression of the 241 ILCP marker CD117 in PC compared to HC groups, while CRTH2 (marker for ILC2s) 242 was decreased in PC compared to both CC and HC groups (Fig. 2B, C). However, 243 the expression of proteins associated with ILC activation, CD56 (also defining NK 244 245 cells with intermediate or high expression levels) and HLA-DR, was not different between groups (Fig. 2B, C). Next, we evaluated total numbers and frequencies of 246 circulating ILCs and NK cells in patients with persistent symptoms after COVID-19 247 infection as compared to convalescent patients and healthy controls. We did not 248 observe significant changes in total ILCs and subsequent ILC subsets (ILC2s, ILC1s, 249 ILCPs) in PC compared to CC and HC groups (Suppl. Fig. 3A). However, PC 250 patients had expanded levels of ILCPs with concurrent decreased ILC2 frequencies, 251 while ILC1 levels remained unchanged (Fig. 2 D, E). The role of ILC2s in viral-252 induced lung pathogenesis remains controversial. Although increased levels of IL-18, 253 IL-13, and IL-6 have been reported along with accumulation of ILC2s during acute 254 COVID-19, increased circulating ILC2s in moderate but not severe COVID-19 255 patients were found in other studies³², consistent with their attrition by IFN-y in type 1 256 (viral-induced) inflammation²⁰. Thus, ILC2s might have important roles in tissue 257 repair during viral-induced epithelial cell damage, perhaps through crosstalk with 258 other ILC subsets. 259

260 Recent work suggested that human ILCPs can interact with endothelial cells, 261 fostering the adhesion of other innate and adaptive immune cells by stimulating pro-

inflammatory cytokine expression of adhesion molecules. This activation occurs 262 through the tumor necrosis factor receptor- and RANK-dependent engagement of 263 $NF-\kappa B$ pathway³³. Nevertheless, PC patients did not show significant changes in 264 CD45RA⁺ ILCPs, although CD56⁺ ILCPs were trending upwards, suggesting a 265 circulating ILCP expansion without overt altered activation (Fig. 2E). Surprisingly, the 266 expression of CD45RA was increased in both ILC1 and ILC2 subsets in the PC 267 group compared to HC (Suppl. Fig. 3B), suggesting the increase of a quiescent 268 local reservoir for the generation of differentiated ILCs³¹. Frequencies of HLA-DR⁺ 269 ILC1s and the transcriptional expression of SLAMF1 within the ILC2 compartment 270 were similar between PC, CC, and HC groups (Suppl. Fig. 3B). We could not find 271 significant differences in NK cell frequencies between patients with PCS, 272 convalescent, and healthy controls (Suppl. Fig. 3C). Together, these data indicate 273 that ILCPs expand in patients with COVID-19 sequelae, without alteration of their 274 activation state. 275

276

277 Concluding remarks

Persistent sequelae following acute COVID-19 are increasingly recognized in 278 convalescent individuals. Our exploratory analyses identified immunological 279 differences in patients with PCS as compared to well-matched convalescent and HC 280 individuals at > 3 months post infection. We found significant changes in circulating 281 ILC subsets, including increased ILCPs and concurrent decreased ILC2 levels. In 282 addition, pro-inflammatory cytokines (IL-8, IL-6), chemokines associated with 283 trafficking of immune cells (CCL19/MIP-3b, FLT3-Ligand) and endothelial 284 inflammation and -repair (CXCL1, EGF, RANTES, PDGF-AA) were elevated in PC 285 participants. Although our work does not dissect how ILCPs or other activated innate 286 and adaptive immune cells, contribute mechanistically to endothelial dysfunction in 287 288 PCS, ILCP expansion along with elevated markers for endothelial inflammation in PC supports their interaction with endothelial cells; thereby facilitating enhanced 289 inflammatory responses and endotheliitis in several organs. These findings may not 290 only be interesting for long-term sequelae of COVID-19, but also for other viral 291 infections that can result in PAIS in convalescent individuals. Further exploration of 292 immunological alterations in PCS may delineate mechanisms of ILC-endothelial cell 293 294 crosstalk and lead to disease-relevant targeted therapies.

Data availability statement: Further information and requests for resources and
reagents should be delivered to and will be fulfilled by the Lead Contact, Julia Roider
(Julia.Roider@med.uni-muenchen.de).

298 Conflict of Interest: The authors declare no commercial or financial conflicts of299 interest.

Ethics approval statement for human studies: KoCo19 Shield: The study protocol 300 was reviewed and approved by the Institutional Review Board of the Medical Faculty 301 at Ludwig-Maximilians-University Munich, Germany under the project number 20-692 302 (vote of approval dated Sept. 21st, 2020) and 20-371 (vote of approval dated May 303 304 15th, 2020). Oral and written informed consent was obtained from all study subjects. PCC: The study protocol was reviewed and approved by the Institutional Review 305 306 Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 21-1165 (vote of approval dated Feb 15, 2021, 307 amendment approved Aug. 11, 2021). Oral and written informed consent was 308 obtained from all study subjects. 309

Patient consent statement: The patients/participants provided their written
 informed consent to participate in this study.

Author contributions: Conception and design: JR and JSK. Cohort initiation, study follow-up, data management and sample processing KoCo19 Shield: MH, MP, CP, IB, LG, NW. Cohort initiation, study follow-up, data management and sample processing PCC: HS, KA, US, JB, GI, EG, MR, CB, AP, EV. Acquisition of data: JSK, SF, VO, HS, MA. Analysis and interpretation of data: JSK and SS. Writing of the manuscript: JSK and JR. Critical reagents and manuscript editing: SF, VO, SS, and MA. Funding acquisition: MH, HS, KA, JSK, JR.

Acknowledgements: We thank Renate Stirner and Gabriele Reiling for excellent 319 technical assistance. The Post-COVID^{LMU} research project is financially supported by 320 the Bavarian State Ministry for Health and Care and the Bavarian State Office for 321 Health and Food Safety (LGL). There is a close link to the nationwide research 322 project "Network University Medicine" (NUM), funded by the Federal Ministry of 323 Education and Research (BMBF) (funding code: 01KX2021) and the NUM-324 associated research projects. JR is supported by the German Center for Infection 325 326 Research (DZIF) and Else Kröner-Fresenius-Stiftung (EKFS). JSK received funding

from the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft), the German Diabetes Society (DDG, Deutsche Diabetes Gesellschaft), and FoeFoLe, LMU Munich. JSK is also supported by the German Society of Internal Medicine (DGIM, Deutsche Gesellschaft für Innere Medizin, Clinician Scientist Program).

- <u>---</u>

- ---

- ~ ^ ^ ^

352 Figures and Figure Legends

Table 1: Clinical and demographic characteristics of study cohorts. Data are given as numbers (percentages). BMI, body mass index. Sex, age and BMI were comparable between groups with an overall mean age of 36 years, 58% females and BMI of 24.2kg/m².

357

Figure 1: Clinical characteristics of study cohorts.

(A) Overview of study cohorts and methods. The figure is partly created withBioRender.com.

361

(B) Demographic characteristics for healthy controls with no prior SARS-CoV-2
infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms
(CC) and convalescent SARS-CoV-2 participants with persisting symptoms (PC)
displayed as ring charts. Statistical significance is shown by capped lines as Chisquare tests for 'Sex' and post-hoc comparisons for 'Age'. Characteristics are further
detailed in Table 1.

- 368 (C) Percentage of hospitalization during acute Covid infection for CC and PC369 participants displayed as ring charts.
- (D) Box plots showing days from first positive PCR test for CC and PC groups.
 Central lines indicate group means; top and bottom lines indicate minimum and
 maximum. Significance was assessed by Mann-Whitney-test.
- (E) Prevalence of top 22 self-reported symptoms in PC participants ranked from
 least prevalent (left) to most prevalent (right). Symptoms are colored according to
 physiological systems. Gastrointestinal (GI), endocrine (Endo), pulmonary (Pulm),
 constitutional (Const), neurological (Neuro), cardiac, and musculoskeletal (MSK).
- $377 \quad ****p \le 0.0001$. See also Table 1.
- 378

Figure 2: Post-COVID participants show altered cytokine expression and levels of innate lymphoid cells.

- (A) Multiplex assay quantification showing plasma levels of IL-8, IL-6, IL-1RA,
 RANTES, FLT-3 Ligand and EGF in healthy controls with no prior SARS-CoV-2
 infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms
 (CC), and convalescent SARS-CoV-2 participants with persisting symptoms (PC) at
 3-10 months after acute COVID infection.
- 386

(B) High-dimensionality reduction analysis of innate lymphoid cells (ILCs, gated as
 lymphocytes, singlets, and CD45⁺CD3⁻Lin⁻CD127⁺ cells as shown in Supplementary
 Figure 3) from peripheral blood mononuclear cells (PBMCs) of HC, CC, and PC
 groups. High-resolution group differences were visualized by calculating Cohen's D

for a given comparison across the t-SNE map. Residual plot showing differences
between maps. Phenotypes within red circles were confirmed to be statistically more
common in PC samples, and phenotypes within blue circles were less common in
PC samples. Analysis is based on flow cytometry data from 32 HC, 32, CC, and 27
PC samples.

(C) Relative expression intensities (combined HC, CC, and PC samples) of
 parameters used in the t-SNE analysis.

(D and E) Representative flow cytometry plots (D) and quantification (D and E),
 showing percent innate lymphoid cell populations in HC, CC, and PC groups at 3-10
 months after acute COVID infection.

- Bar graphs indicate mean (±SE), n=27-32 individuals per group, unpaired t-test (A, D, E), *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001, ****p \leq 0.0001. See also Supplementary Figure 1.

425 Materials and Methods

426 Study design

427 KoCo19-Shield sub study of the prospective Covid19 cohort Munich -Index 428 study (KoCo19-Index)

To establish the KoCo19-index cohort, we recruited study subjects in whose 429 household at least one person had a PCR confirmed SARS-CoV-2 infection. 430 Recruitment was performed as previously described³⁴. In brief, individuals with PCR 431 confirmed SARS-CoV2 infection were contacted by the responsible official 432 433 authorities (City of Munich Health department) in May and June 2020. Individuals who expressed interest in participating were enrolled in the KoCo19 index study. For 434 the KoCo19 – Shield sub study, at least one member of the participant's household 435 (> 14 years old) also had to be willing to participate. The KoCo19-Shield sub study 436 comprised 177 PCR-positive individuals and 145 household members, enrolled 437 438 between September 29, 2020, and January 27, 2021. Personal data of the study subjects was collected as previously described³⁵. In short, the mobile data collection 439 440 tool OpenDataKit (ODK) was used to capture data during study visits by field workers on Android smartphones. Study subjects completed 441 household 442 questionnaires as well as personal questionnaires using a web-based application. Non-responders were reminded first by email, and in case of continued non-443 response with a telephone reminder. Telephone interviews were offered to those 444 who felt unable to complete the questionnaires online. Clinical demographics of 445 study participants are reported in Table 1. 446

The study was approved by the Ethics Committee of the Medical Faculty at LMU Munich (20–275 V) and the protocol is available online (www.koco19.de)³⁴. Informed consent was obtained from all enrolled participants. The study is registered to the German Clinical Trials Register (DRKS-ID: DRKS00022155).

451

452 Post Covid Study

Post-COVID-Care (PCC) study is an ongoing prospective single-center study comprised of patients with persistent symptoms following acute COVID-19. Participants with COVID-19 sequelae were recruited from the Post-COVID outpatient clinic at the University Hospital LMU Munich. Samples were collected from participants enrolled between April and July 2022. Inclusion criteria were age \geq 18

years; persistent symptoms > 12 weeks within 6 months following initial COVID-19 458 infection. Pre-specified exclusion criteria were other explanations for the symptom 459 onset or complete resolution of symptoms. All participants were scheduled for follow-460 up for at least 6 months and up to 24 months if symptoms persisted. At baseline and 461 during the routine follow-up visits blood samples were obtained and each patient 462 completed progressive web app (PWA)-based questionnaires (LCARS-C, LMU 463 Munich). Patients who did not undergo any follow-up on site were asked to fill out the 464 follow-up surveys using the PWA-based questionnaire at home using a PC, 465 466 smartphone or tablet. Informed consent was obtained from all participants before inclusion into the study. Clinical characteristics of study participants are reported in 467
Table 1. The study was approved by the Ethics Committee of the Medical Faculty at
 468 LMU Munich (No. 21-1165) and registered to the German Clinical Trials Register 469 (DRKS-ID: DRKS00030974). 470

471

472 Participant Surveys

KoCo19 and PCC study participants completed a comprehensive suite of surveys, 473 combining validated patient-reported outcomes (PROs) with custom, purpose-474 475 developed tools by the study team. Baseline demographic data collected from surveys included gender, age, body mass index (BMI), race, and medical 476 477 comorbidities. Additionally, participants in the Long COVID and convalescent group were asked to provide COVID-19 clinical data including date of symptom onset and 478 acute disease severity (non-hospitalized vs. hospitalized), SARS-CoV-2 polymerase 479 chain reaction (PCR) diagnostic testing results, and SARS-CoV-2 antibody testing 480 results. All participants were asked to report SARS-CoV-2 vaccination status 481 including date of vaccinations and vaccine brand. 482

483

484 Blood sample processing

Whole blood was collected in four potassium-EDTA-coated blood collection tubes (Sarstedt) from participants at University Hospital, LMU, Munich, Germany. Following blood draw, all participant samples were assigned unique study identifiers and de-identified by research staff. Blood samples were processed the same day as collection. Plasma samples were collected after centrifugation of whole blood at 450×g for 10 minutes at room temperature (RT). Plasma was then transferred to 1,8ml polyethylene CryotubeTM vials (ThermoFisher), aliguoted, and stored at -80°C. For

isolation of peripheral blood mononuclear cells (PBMCs), two tubes each of the 492 remaining whole blood sample were pooled and filled up to a total volume of 32.5 ml 493 with Hank's Balanced Salts Solution (Capricorn or Sigma). 13,5ml Histopague®-494 1077 (Sigma) were added at the bottom of each tube and samples were centrifuged 495 at 450xg for 30 minutes at RT without break. PBMC layer on top of the Histopague® 496 layer was collected and washed twice in Hank's balanced salts solution. Isolated 497 cells were counted using a CASY cell counter and analyzer (Schärfe System GmbH) 498 before storage in liquid nitrogen at -180°C for cryopreservation. 499

500

501 Flow cytometry

Cryopreserved PBMCs were thawed in a 37°C water bath, pipetted into Iscove's 502 Modified Dulbecco'sMedium (IMDM) supplemented with 10% FCS medium, and 503 washed by centrifugation. Three to six million cells per sample were incubated with 504 antibodies to surface antigens (Table S1) for 30 minutes at 4°C, washed with FACS 505 buffer (1XDPBS, 3% FCS, 0.05% NaN3), fixed with 2% paraformaldehyde for 10 506 minutes, washed again with FACS buffer, and resuspended in FACS buffer. Flow 507 cytometry was performed on BD LSRFortessa X-20. Fluorochrome compensation 508 509 was performed with single-stained UltraComp eBeads (Invitrogen, Cat# 01-2222-42). Samples were FSC-A/SSC-A gated to exclude debris, followed by FSC-H/FSC-A 510 gating to select single cells and Zombie NIR fixable or DAPI to exclude dead cells. 511 Innate lymphoid cells were identified as lineage negative (CD1a, CD14, CD19, 512 CD34⁻, CD94⁻, CD123⁻, FcER1a⁻, TCRab⁻, TCRgd⁻, BDCA2⁻), CD45⁺, CD161⁺, 513 CD127⁺, as indicated. The full gating strategy is shown in Fig. S1 and was adapted 514 from previous work²⁹. Data were analyzed using FlowJo version 10.7 software 515 (TreeStar, USA) and compiled using Prism (GraphPad Software). T-distributed 516 stochastic neighbor embedding (t-SNE) visualization of flow cytometry data was 517 performed using Cytobank. 518

519

520 Quantification of plasma cytokine levels

The plasma levels of 46 molecular species were quantified using a Luminex platform
(Human Cytokine Discovery, R&D System, Minneapolis, MN) for the simultaneous
detection of the following molecules: G-CSF, PDGF-AA, EGF, PDGF-AB/BB, VEGF,
GM-CSF, FGF, GRZB, IL-1A, IL-1RA, IL-2, IL-27, IL-4, IL-6, IL-10, IL-13, TNF, IL-

17C, IL-11, IL-18, IL-23, IL-6RA, IL-19, IFN-B, IL-3, IL-5, IL-7, IL-12p70, IL-15, IL-33,
TGF-B, IFN-G, IL-1B, IL-17, IL-17E, CCL3, CCL11, CCL20, CXCCL1, CXCL2,
CCL5, CCL2, CCL4, CCL19, CXCL1, CXCL10, PD-L1, FLT-3, TACI, FAS, LEPTIN
R, APRIL, OPN, BAFF, LEPTIN, BMP4, CD40 LIGAND, FAS LIGAND, BMP7,
BMP2, and TRAIL, according to the manufacturer's instruction

530 Statistical analysis

All data are expressed as means \pm standard error of the mean (SEM) unless otherwise noted. Comparisons between two groups were analyzed by using unpaired two-tailed Student's t-tests, and multiple comparisons were analyzed by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test (Prism, GraphPad Software, La Jolla, CA), with * = p<0.05, ** = p<0.01, *** =p<0.001, **** =p<0.0001. Each symbol reflects individuals for flow analysis or plasma cytokine levels.

538

Unsupervised data analysis. Cytobank³⁶ was used for initial manual gating of 539 Lineage-negative cells and ILC subsets ILC1, ILC2, and ILCP, using the same gating 540 strategy as described above. FCS files were transformed with. Lineage-negative 541 cells were subjected to dimensionality reduction using Cytobank opt-SNE with 542 default hyperparameters and following embedding markers with normalized scales 543 Cytobank arcsinh transformation: CD117, CD127, CD161, CD45RA, CD56, CRTH2, 544 HLA-DR, and SLAMF1. All pre-gated events were used without prior downsampling 545 from 91 samples. In order to perform downstream statistical analyses in R 546 (http://www.r-project.org/) and visualize t-SNE maps across the 91 samples, events 547 within ILC subsets were exported from Cytobank as tab-separated values containing 548 compensated and transformed marker expression levels as well as t-SNE 549 coordinates and metacluster assignment. T-SNE plots were generated after 550 subsampling each sample to contain a maximum of 2500 events. High-resolution 551 group differences were visualized by calculating Cohen's D for a given comparison 552 across the t-SNE map. To this end, we generated adaptive 2D histograms using the 553 probability binning algorithm available through the R *flowFP* package³⁷. Dependent 554 on the total number of cells available, a single binning model was created on 555 collapsed data from all samples, by recursively splitting the events at the median 556 557 values along the two t-SNE dimensions. We chose a grid of 256 bins to have, on

average, at least eight cells per bin in each sample for statistical accuracy. Since 558 there was a significant difference between cellular frequency distributions between 559 the six measurement days, the batch effect was first regressed out by fitting a linar 560 model to each bin after applying the arcsine-square-root transformation for 561 proportions. The group-difference effect sizes were then calculated for each bin 562 using the cohen.d function of the effsize package. In order to get a smoothed 563 representation of the effect size map, adaptive binning was performed on a series of 564 rotated coordinates and per cell-averaged effect size values were used to color-565 566 encode each cell throughout the t-SNE map. All analyses were performed using R version 4.1.1, available free online at https://www.r-project.org. 567

568

569 **Post Covid Care group members**

Kristina Adorjan, Shahnaz C. Azad, Petra Bäumler, Christopher Bensch, Johannes
Bogner, Svenja Anike Feldmann, Fides Heimkes, Gerardo Ibarra, Dominik Irnich,
Anna-Lena Johlke, Stefan Kääb, Kathrin Kahnert, Eduard Kraft, Katrin MilgerKneidinger, Veronica Ober, Anna Pernpruner, Jan Rémi, Julia Roider, Michael
Ruzicka, Simone Sachenbacher, Florian Schöberl, Konstantin Stark, Andreas
Straube, Hans Christian Stubbe, Elisabeth Valdinoci, Martin Weigl, Nora Wunderlich.

577 KoCo19 study group members

Emad Alamoudi, Jared Anderson, Abhishek Bakuli, Marc Becker, Franziska 578 Bednarzki, Olimbek Bemirayev, Jessica Beyerl, Patrick Bitzer, Rebecca Boehnlein, 579 Friedrich Caroli, Lorenzo Contento, Alina Czwienzek, Flora Deák, Maximilian N. 580 Diefenbach, Gerhard Dobler, Jürgen Durner, Judith Eckstein, Philine Falk, Volker 581 Fingerle, Felix Forster, Turid Frahnow, Guenter Froeschl, Otto Geisenberger, 582 Kristina Gillig, Philipp Girl, Pablo Gutierrez, Anselm Haderer, Marlene Hannes, Jan 583 Hasenauer, Tim Haselwarter, Alejandra Hernandes, Matthias Herrmann, Leah Hillari, 584 Christian Hinske, Tim Hofberger, Sacha Horn, Kristina Huber, Christian Janke, 585 Ursula Kappl, Antonia Kessler, Zohaib N. Khan, Johanna Kresin, Arne Kroidl, 586 Magdalena Lang, Silvan Lange, Michael Laxy, Ronan Le Gleut, Reiner Leidl, 587 Leopold Liedl, Xhovana Lucaj, Petra Mang, Alisa Markgraf, Rebecca Mayrhofer, 588 Dafni Metaxa, Hannah Mueller, Katharina Mueller, Laura Olbrich, Ivana Paunovic, 589 Claire Pleimelding, Michel Pletschette, Stephan Prueckner, Kerstin Puchinger, Peter 590

Puetz, Katja Radon, Elba Raimundéz, Jakob Reich, Friedrich Riess, Camilla Rothe,
Viktoria Ruci, Nicole Schaefer, Yannik Schaelte, Benedikt Schluse, Elmar Saathoff,
Lara Schneider, Mirjam Schunk, Lars Schwettmann, Peter Sothmann, Kathrin Strobl,
Jeni Tang, Fabian Theis, Verena Thiel, Jonathan von Lovenberg, Julia Waibel,
Claudia Wallrauch, Roman Woelfel, Julia Wolff, Tobias Wuerfel, Sabine Zange,
Eleftheria Zeggini, Anna Zielke.

- 597
- 598

599 **References**

- Clark D V, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. *Lancet Infect Dis.* 2015;15(8):905-912. doi:10.1016/S1473-3099(15)70152-0
- A Post-Graduate Lecture ON THE NERVOUS SEQUELÆ OF INFLUENZA.
 Lancet. 1893;142(3645):73-76. doi:https://doi.org/10.1016/S0140 6736(00)65088-2
- Fluge Ø, Tronstad KJ, Mella O. Pathomechanisms and possible interventions
 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *J Clin Invest.* 2021;131(14). doi:10.1172/JCI150377
- A. Newton DJ, Kennedy G, Chan KKF, Lang CC, Belch JJF, Khan F. Large and
 small artery endothelial dysfunction in chronic fatigue syndrome. *Int J Cardiol.*2012;154(3):335-336. doi:10.1016/j.ijcard.2011.10.030
- 5. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the
 Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute
 Infection and Public Health Implications. *JAMA*. 2020;324(22):2251-2252.
 doi:10.1001/jama.2020.22717
- 616 6. Sivan M, Taylor S. NICE guideline on long covid. *BMJ*. 2020;371:m4938. 617 doi:10.1136/bmj.m4938
- 618 7. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms,
 619 risk factors, and management. *BMJ*. 2021;374:n1648. doi:10.1136/bmj.n1648
- 8. Margalit I, Yelin D, Sagi M, et al. Risk Factors and Multidimensional
 Assessment of Long Coronavirus Disease Fatigue: A Nested Case-Control
 Study. *Clin Infect Dis.* 2022;75(10):1688-1697. doi:10.1093/cid/ciac283
- 623 9. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection 624 syndromes. *Nat Med*. 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
- Kreutmair S, Unger S, Núñez NG, et al. Distinct immunological signatures
 discriminate severe COVID-19 from non-SARS-CoV-2-driven critical
 pneumonia. *Immunity*. 2021;54(7):1578-1593.e5.
 doi:10.1016/j.immuni.2021.05.002
- 11. Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that

delayed bystander CD8+ T cell activation and early immune pathology 630 distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257-631 1275.e8. doi:10.1016/j.immuni.2021.05.010 632 12. Blot M, Bour J-B, Quenot JP, et al. The dysregulated innate immune response 633 in severe COVID-19 pneumonia that could drive poorer outcome. J Transl 634 Med. 2020;18(1):457. doi:10.1186/s12967-020-02646-9 635 Lim J, Puan KJ, Wang LW, et al. Data-Driven Analysis of COVID-19 Reveals 13. 636 Persistent Immune Abnormalities in Convalescent Severe Individuals . Front 637 Immunol . 2021;12. 638 https://www.frontiersin.org/articles/10.3389/fimmu.2021.710217 639 14. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and 640 endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. 641 doi:10.1016/S0140-6736(20)30937-5 642 15. Cheon IS, Li C, Son YM, et al. Immune signatures underlying post-acute 643 COVID-19 lung sequelae. Sci Immunol. 2022;6(65):eabk1741. 644 doi:10.1126/sciimmunol.abk1741 645 16. Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID 646 identified through immune profiling. *medRxiv*. Published online January 647 2022:2022.08.09.22278592. doi:10.1101/2022.08.09.22278592 648 17. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction 649 persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. 650 Nat Immunol. 2022;23(2):210-216. doi:10.1038/s41590-021-01113-x 651 18. Moro K, Yamada T, Tanabe M, et al. Innate production of TH2 cytokines by 652 adipose tissue-associated c-Kit+Sca-1+ lymphoid cells. Nature. 653 2010;463(7280):540-544. doi:10.1038/nature08636 654 19. Vivier E, Artis D, Colonna M, et al. Innate Lymphoid Cells: 10 Years On. Cell. 655 656 2018;174(5):1054-1066. doi:10.1016/j.cell.2018.07.017 20. Cautivo KM, Matatia PR, Lizama CO, et al. Interferon gamma constrains type 657 2 lymphocyte niche boundaries during mixed inflammation. Immunity. 658 2022;55(2):254-271.e7. doi:10.1016/j.immuni.2021.12.014 659 660 21. Dahlgren MW, Molofsky AB. All along the watchtower: group 2 innate lymphoid cells in allergic responses. Curr Opin Immunol. 2018;54:13-19. 661 22. Gomez-Cadena A, Spehner L, Kroemer M, et al. Severe COVID-19 patients 662 exhibit an ILC2 NKG2D+ population in their impaired ILC compartment. Cell 663 Mol Immunol. 2021;18(2):484-486. doi:10.1038/s41423-020-00596-2 664 23. Silverstein NJ, Wang Y, Manickas-Hill Z, et al. Innate lymphoid cells and 665 COVID-19 severity in SARS-CoV-2 infection. Giamarellos-Bourboulis EJ, Rath 666 S, Giamarellos-Bourboulis EJ, Kyriazopoulou E, eds. Elife. 2022;11:e74681. 667 doi:10.7554/eLife.74681 668 24. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of 669 post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom 670 Study app: a prospective, community-based, nested, case-control study. 671 Lancet Infect Dis. 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-6 672

673 674 675	25.	Magnusson K, Kristoffersen DT, Dell'Isola A, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. <i>Nat Commun</i> . 2022;13(1):7363. doi:10.1038/s41467-022-35240-2
676 677 678	26.	Kaiser R, Leunig A, Pekayvaz K, et al. Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. <i>JCI Insight</i> . 2021;6(18). doi:10.1172/jci.insight.150862
679 680 681	27.	Zhang Z, Ai G, Chen L, et al. Associations of immunological features with COVID-19 severity: a systematic review and meta-analysis. <i>BMC Infect Dis</i> . 2021;21(1):738. doi:10.1186/s12879-021-06457-1
682 683 684	28.	Sabbatino F, Conti V, Franci G, et al. PD-L1 Dysregulation in COVID-19 Patients . <i>Front Immunol</i> . 2021;12. https://www.frontiersin.org/articles/10.3389/fimmu.2021.695242
685 686 687	29.	Mazzurana L, Bonfiglio F, Forkel M, D'Amato M, Halfvarson J, Mjösberg J. Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells. <i>Inflamm Bowel Dis</i> . 2021;27(7):1128-1138. doi:10.1093/ibd/izaa316
688 689 690	30.	Lim AI, Li Y, Lopez-Lastra S, et al. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. <i>Cell</i> . 2017;168(6):1086-1100.e10. doi:10.1016/j.cell.2017.02.021
691 692 693 694	31.	Kokkinou E, Pandey RV, Mazzurana L, et al. CD45RA+CD62L- ILCs in human tissues represent a quiescent local reservoir for the generation of differentiated ILCs. <i>Sci Immunol.</i> 2023;7(70):eabj8301. doi:10.1126/sciimmunol.abj8301
695 696	32.	Fonseca W, Lukacs NW, Elesela S, Malinczak C-A. Role of ILC2 in Viral- Induced Lung Pathogenesis . <i>Front Immunol</i> . 2021;12.
697 698 699	33.	Vanoni G, Ercolano G, Candiani S, et al. Human primed ILCPs support endothelial activation through NF-κB signaling. Cerullo V, Taniguchi T, eds. <i>Elife</i> . 2021;10:e58838. doi:10.7554/eLife.58838
700 701 702 703	34.	Brand I, Gilberg L, Bruger J, et al. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay . <i>Front Immunol</i> . 2021;12.
704 705 706	35.	Pritsch M, Radon K, Bakuli A, et al. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. <i>Int J Environ Res Public Health</i> . 2021;18(7). doi:10.3390/ijerph18073572
707 708 709	36.	Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. <i>Curr Protoc Cytom</i> . 2010;Chapter 10:Unit10.17-Unit10.17. doi:10.1002/0471142956.cy1017s53
710 711 712	37.	Rogers WT, Holyst HA. FlowFP: A Bioconductor Package for Fingerprinting Flow Cytometric Data. Gottardo R, ed. <i>Adv Bioinformatics</i> . 2009;2009:193947. doi:10.1155/2009/193947
713		
714		

Figure 1



Figure 2



Table 1. Clinical characteristics of patient cohorts

	Healthy Controls (HC)	Convalescent Controls (CC)	Post Covid (PC)
n	32	32	27
Sex			
Male	15 (46.9%)	14 (43.8%)	9 (33.3%)
Female	17 (53.1%)	18 (56.2%)	18 (66.7%)
Age (years)			
20-29	6 (18.8%)	6 (18.8%)	4 (14.8%)
30-39	10 (31.2%)	12 (37.5%)	10 (37.0%)
40-49	15 (46.9%)	12 (37.5%)	8 (29.6%)
>49	1 (3.1%)	2 (6.2%)	5 (18.5%)
Mean	36	36	37
BMI (kg/m ²)			
<18.5	3 (9.4%)	0 (0%)	0 (0%)
18,5-25	14 (43.8%)	22 (68.8%)	15 (55.6%)
25-30	10 (31.2%)	9 (28.1%)	4 (14.8%)
>30	5 (13.6%)	1 (3.1%)	3 (11.1%)
Mean	25.2	23.4	24
Time from PCR to visit			
median (in days)		273 (Min:125; Max: 318)	113 (Min: 89; Max: 292)
Data are given as numbers (p	ercentages). BMI, body mass ind	lex.	· · · ·

Sex, age and BMI were comparable between groups with an overall mean age of 36 years, 58% females and BMI of 24.2kg/m2